Real-World Assessment of Switching from a Dipeptidyl Peptidase-4 Inhibitor to Exenatide Once-Weekly in Patients with Type 2 Diabetes

被引：0
|
作者：
Gorgojo-Martinez, Juan J.
Gargallo-Fernandez, Manuel A.
Brito-Sanfiel, Miguel A.
Lisbona-Catalan, Arturo
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1118-P
引用
收藏
页码：A297 / A297
页数：1
相关论文
共 50 条
  • [31] Saxagliptin A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes
    Lam, Sum
    Saad, Maha
    CARDIOLOGY IN REVIEW, 2010, 18 (04) : 213 - 217
  • [32] Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus
    Yoneda, Chihiro
    Kobayashi, Junji
    Kuribayashi, Nobuichi
    DIABETOLOGY INTERNATIONAL, 2024, 15 (03) : 569 - 576
  • [33] Real-World Use of Exenatide Once-Weekly Compared with Basal Insulin among Type 2 Diabetic Patients with Renal Impairment
    Loughlin, Anita M.
    Qiao, Qing
    Johnsson, Kristina M.
    Grandy, Susan
    Ezzy, Stephen
    Yochum, Laura
    Clifford, C. Robin
    Gately, Robert
    Nunes, Anthony P.
    Dore, David D.
    Seeger, John D.
    DIABETES, 2016, 65 : A275 - A275
  • [34] Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
    Menzen, Markus
    Berentzen, Tina Landsvig
    Catarig, Andrei-Mircea
    Pieperhoff, Sebastian
    Simon, Joerg
    Jacob, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) : 205 - 215
  • [35] Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review
    Ruan, Zhen
    Jiang, Yixuan
    Shi, Honghao
    Jia, Ruxu
    Ung, Carolina Oi Lam
    Hu, Hao
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (02) : 161 - 176
  • [36] Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
    Holman, Rury R.
    Bethel, M. Angelyn
    Mentz, Robert J.
    Thompson, Vivian P.
    Lokhnygina, Yuliya
    Buse, John B.
    Chan, Juliana C.
    Choi, Jasmine
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Marso, Steven P.
    Ohman, Peter
    Pagidipati, Neha J.
    Poulter, Neil
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13): : 1228 - 1239
  • [37] Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes - Randomized controlled study -
    Oita, Mayuko
    Miyoshi, Hideaki
    Ono, Kota
    Nakamura, Akinobu
    Cho, Kyu Yong
    Nomoto, Hiroshi
    Yamamoto, Kohei
    Omori, Kazuno
    Manda, Naoki
    Kurihara, Yoshio
    Aoki, Shin
    Atsumi, Tatsuya
    ENDOCRINE JOURNAL, 2018, 65 (02) : 141 - 150
  • [38] Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men
    Tsuchiya, Saori
    Friedman, Evan
    Addy, Carol
    Wakana, Akira
    Tatosian, Daniel
    Matsumoto, Yuki
    Suzuki, Hideyo
    Kauh, Eunkyung
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (01) : 84 - 92
  • [39] Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
    Dave, Darshan J.
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2011, 2 (04) : 230 - 235
  • [40] Exenatide extended-release: A once-weekly option for patients with type 2 diabetes
    Anderson, Zachary L.
    Clements, Jennifer N.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2014, 27 (06): : 44 - 46
12345